Azithromycin to prevent post-discharge morbidity and mortality in Kenyan children: a protocol for a randomised, double-blind, placebo-controlled trial (the Toto Bora trial)

Patricia B Pavlinac, Benson O Singa, Grace C John-Stewart, Barbra A Richardson, Rebecca L Brander, Christine J McGrath, Kirkby D Tickell, Mary Amondi, Doreen Rwigi, Joseph B Babigumira, Sam Kariuki, Ruth Nduati, Judd L Walson, Patricia B Pavlinac, Benson O Singa, Grace C John-Stewart, Barbra A Richardson, Rebecca L Brander, Christine J McGrath, Kirkby D Tickell, Mary Amondi, Doreen Rwigi, Joseph B Babigumira, Sam Kariuki, Ruth Nduati, Judd L Walson

Abstract

Introduction: Child mortality due to infectious diseases remains unacceptably high in much of sub-Saharan Africa. Children who are hospitalised represent an accessible population at particularly high risk of death, both during and following hospitalisation. Hospital discharge may be a critical time point at which targeted use of antibiotics could reduce morbidity and mortality in high-risk children.

Methods and analysis: In this randomised, double-blind, placebo-controlled trial (Toto Bora Trial), 1400 children aged 1-59 months discharged from hospitals in Western Kenya, in Kisii and Homa Bay, will be randomised to either a 5-day course of azithromycin or placebo to determine whether a short course of azithromycin reduces rates of rehospitalisation and/or death in the subsequent 6-month period. The primary analysis will be modified intention-to-treat and will compare the rates of rehospitalisation or death in children treated with azithromycin or placebo using Cox proportional hazard regression. The trial will also evaluate the effect of a short course of azithromycin on enteric and nasopharyngeal infections and cause-specific morbidities. We will also identify risk factors for postdischarge morbidity and mortality and subpopulations most likely to benefit from postdischarge antibiotic use. Antibiotic resistance in Escherichia coli and Streptococcus pneumoniae among enrolled children and their primary caregivers will also be assessed, and cost-effectiveness analyses will be performed to inform policy decisions.

Ethics and dissemination: Study procedures were reviewed and approved by the institutional review boards of the Kenya Medical Research Institute, the University of Washington and the Kenyan Pharmacy and Poisons Board. The study is being externally monitored, and a data safety and monitoring committee has been assembled to monitor patient safety and to evaluate the efficacy of the intervention. The results of this trial will be published in peer-reviewed scientific journals and presented at relevant academic conferences and to key stakeholders.

Trial registration number: NCT02414399.

Keywords: child mortality; post-discharge interventions; targeted empiric antibiotic therapy; toto bora trial.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Power and detectable HRs assuming a range of mortality rates from 2% to 17%.

References

    1. GBD 2015 Child Mortality Collaborators. Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1725–74. 10.1016/S0140-6736(16)31575-6
    1. Moïsi JC, Gatakaa H, Berkley JA, et al. . Excess child mortality after discharge from hospital in Kilifi, Kenya: a retrospective cohort analysis. Bull World Health Organ 2011;89:725–32. 10.2471/BLT.11.089235
    1. Veirum JE, Sodeman M, Biai S, et al. . Increased mortality in the year following discharge from a paediatric ward in Bissau, Guinea-Bissau. Acta Paediatr 2007;96:1832–8. 10.1111/j.1651-2227.2007.00562.x
    1. Snow RW, Howard SC, Mung’Ala-Odera V, et al. . Paediatric survival and re-admission risks following hospitalisation on the Kenyan coast. Trop Med Int Health 2000;5:377–83. 10.1046/j.1365-3156.2000.00568.x
    1. Zucker JR, Lackritz EM, Ruebush TK, et al. . Childhood mortality during and after hospitalisation in western Kenya: effect of malaria treatment regimens. Am J Trop Med Hyg 1996;55:655–60. 10.4269/ajtmh.1996.55.655
    1. Islam MA, Rahman MM, Mahalanabis D, et al. . Death in a diarrhoeal cohort of infants and young children soon after discharge from hospital: risk factors and causes by verbal autopsy. J Trop Pediatr 1996;42:342–7. 10.1093/tropej/42.6.342
    1. Villamor E, Misegades L, Fataki MR, et al. . Child mortality in relation to HIV infection, nutritional status, and socio-economic background. Int J Epidemiol 2005;34:61–8. 10.1093/ije/dyh378
    1. Phiri KS, Calis JC, Faragher B, et al. . Long term outcome of severe anaemia in Malawian children. PLoS One 2008;3:e2903 10.1371/journal.pone.0002903
    1. Wiens MO, Pawluk S, Kissoon N, et al. . Pediatric post-discharge mortality in resource poor countries: a systematic review. PLoS One 2013;8:e66698 10.1371/journal.pone.0066698
    1. Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, et al. . A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med 2014;370:41–53. 10.1056/NEJMoa1214901
    1. Walker AS, Mulenga V, Ford D, et al. . The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis 2007;44:1361–7. 10.1086/515396
    1. Chintu C, Bhat GJ, Walker AS, et al. . Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004;364:1865–71. 10.1016/S0140-6736(04)17442-4
    1. Trehan I, Goldbach HS, LaGrone LN, et al. . Antibiotics as part of the management of severe acute malnutrition. N Engl J Med 2013;368:425–35. 10.1056/NEJMoa1202851
    1. Lockman S, Hughes M, Powis K, et al. . Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, randomised, placebo-controlled trial. Lancet Glob Health 2017;5:e491–e500. 10.1016/S2214-109X(17)30143-2
    1. Berkley JA, Ngari M, Thitiri J, et al. . Daily co-trimoxazole prophylaxis to prevent mortality in children with complicated severe acute malnutrition: a multicentre, double-blind, randomised placebo-controlled trial. Lancet Glob Health 2016;4:e464–e473. 10.1016/S2214-109X(16)30096-1
    1. Porco TC, Gebre T, Ayele B, et al. . Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 2009;302:962–8. 10.1001/jama.2009.1266
    1. Keenan JD, Ayele B, Gebre T, et al. . Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis 2011;52:883–8. 10.1093/cid/cir069
    1. O’Brien KL, Nohynek H. World Health Organisation Pneumococcal Vaccine Trials Carraige Working Group. Report from a WHO working group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J 2003;22:133–40. 10.1097/01.inf.0000048676.93549.d1
    1. Satzke C, Turner P, Virolainen-Julkunen A, et al. . Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organisation Pneumococcal Carriage Working Group. Vaccine 2013;32:165–79. 10.1016/j.vaccine.2013.08.062
    1. Serina P, Riley I, Stewart A, et al. . A shortened verbal autopsy instrument for use in routine mortality surveillance systems. BMC Med 2015;13:302 10.1186/s12916-015-0528-8
    1. Serina P, Riley I, Stewart A, et al. . Improving performance of the Tariff Method for assigning causes of death to verbal autopsies. BMC Med 2015;13:291 10.1186/s12916-015-0527-9
    1. WHO. Making choices in health: WHO guide to cost-effectiveness analysis, 2003.
    1. Murray CJ, Vos T, Lozano R, et al. . Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197–223. 10.1016/S0140-6736(12)61689-4
    1. Salomon JA, Vos T, Hogan DR, et al. . Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012;380:2129–43. 10.1016/S0140-6736(12)61680-8
    1. Gold M, Siegel JE, Russell LB, et al. . Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
    1. Drummond MF, Torrance GW, O’Brien BJ, et al. . Methods for the economic evaluation of healthcare programmes. 3rd edn New York: Oxford University Press, 2005.
    1. Laxminarayan R, Mills AJ, Breman JG, et al. . Advancement of global health: key messages from the Disease Control Priorities Project. Lancet 2006;367:1193–208. 10.1016/S0140-6736(06)68440-7
    1. Jamison DT, Measham A, Alleyne G, et al. . Disease control priorities in developing countries. 2nd edn: Oxford University Press, 2006.
    1. Abdullahi O, Karani A, Tigoi CC, et al. . The prevalence and risk factors for pneumococcal colonisation of the nasopharynx among children in Kilifi District, Kenya. PLoS One 2012;7:e30787 10.1371/journal.pone.0030787
    1. Rodrigues F, Foster D, Caramelo F, et al. . Progressive changes in pneumococcal carriage in children attending daycare in Portugal after 6 years of gradual conjugate vaccine introduction show falls in most residual vaccine serotypes but no net replacement or trends in diversity. Vaccine 2012;30:3951–6. 10.1016/j.vaccine.2012.03.058
    1. Grivea IN, Tsantouli AG, Michoula AN, et al. . Dynamics of Streptococcus pneumoniae nasopharyngeal carriage with high heptavalent pneumococcal conjugate vaccine coverage in Central Greece. Vaccine 2011;29:8882–7. 10.1016/j.vaccine.2011.09.074
    1. Skalet AH, Cevallos V, Ayele B, et al. . Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med 2010;7:e1000377 10.1371/journal.pmed.1000377
    1. Adetifa IM, Antonio M, Okoromah CA, et al. . Pre-vaccination nasopharyngeal pneumococcal carriage in a Nigerian population: epidemiology and population biology. PLoS One 2012;7:e30548 10.1371/journal.pone.0030548
    1. Hill PC, Akisanya A, Sankareh K, et al. . Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers. Clin Infect Dis 2006;43:673–9. 10.1086/506941

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit